NanoSALV was used to treat a diabetic foot ulcer in a 58-year old male patient. The patient presented type 2 diabetes mellitus with 13 years of evolution. This patient was already scheduled for amputation. In order to avoid the amputation, the patient was included into the clinical trial and treated with NanoSALV. In this case, NanoSALV was successful at treating the diabetic foot ulcer to avoid the already prescribed amputation. After a month of treatment, the necrotic tissue of the toes disappeared presenting complete epithelialization below them. After 2 months of treatment, the injury in the base of the heel was completely clean and had a multiplying granulating tissue. In conclusion, NanoSALV was successful in treating the patient’s diabetic foot ulcer.
